GlassScriptPhysician profile
Amanda M Evans
NPI 1528480639
$8,768.25
in general payments reported to CMS, 2019-2025
32 companies · $38.04 in 2025
The $38.04 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,553 · 2022: $2,777 · 2023: $3,340 · 2024: $60.17 · 2025: $38.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,438.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,295.32 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $886.22 | 2021-2023 | Repatha, Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $820.77 | 2021-2023 | Breztri, Farxiga |
| Pfizer INC. | $814.22 | 2021-2023 | |
| Abbvie INC. | $730.32 | 2021-2023 | |
| Lilly USA, LLC | $545.90 | 2021-2023 | Mounjaro, Emgality, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $420.70 | 2021-2023 | Synjardy, Stiolto Respimat, Tradjenta |
| Merck Sharp & Dohme LLC | $366.21 | 2021-2023 | Belsomra, Verquvo, Lagevrio |
| Abbott Laboratories | $339.63 | 2021-2023 | Freestyle Libre 2, Infinity, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $301.12 | 2021-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.81 | 2021-2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $293.62 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $286.62 | 2021-2023 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $212.14 | 2022 | |
| Idorsia Pharmaceuticals US INC | $153.72 | 2023 | Quviviq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $150.70 | 2021 | |
| Novartis Pharmaceuticals Corporation | $137.99 | 2021-2023 | |
| Astellas Pharma US INC | $127.16 | 2021 | |
| Esperion Therapeutics, INC. | $97.63 | 2021-2023 | Nexletol |
| Amarin Pharma, INC. | $93.51 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $79.17 | 2023 | Austedo Xr, Austedo |
| Paratek Pharmaceuticals, INC. | $60.72 | 2022 | |
| Sumitomo Pharma America, INC. | $45.75 | 2023 | Gemtesa |
| Shield Therapeutics INC | $41.50 | 2023 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $40.25 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $30.42 | 2023 | |
| Dynavax Technologies Corporation | $22.88 | 2023 | Heplisav-B |
| Abiomed | $21.52 | 2025 | |
| Radius Health, INC. | $15.18 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.99 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $14.63 | 2023 | Uptravi, Opsumit |
| Medtronic, INC. | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.